BREA,
Calif. and TEL AVIV,
Israel, Sept. 17, 2024 /PRNewswire/
-- Beckman Coulter, a clinical diagnostics leader, and Scopio
Labs, a medtech company that develops digital cell morphology
workflow solutions, today jointly announced expansion of its
long-term partnership to include a global distribution agreement of
Scopio's Full-Field Bone Marrow Aspirate™ (FF-BMA) Application.
Scopio's X100 / X100HT with FF-BMA Application are CE-Marked.
Bone marrow aspirate analysis is a vital procedure providing
essential information for the assessment of various hematologic
diseases.i By aspirating a small sample of the
liquid portion of bone marrow, clinicians can examine the cellular
composition, as well as the morphology and maturity of the blood
cells morphology. However, traditional BMA analysis uses manual,
labor-intensive, time-consuming methods that are heavily reliant on
highly skilled hematopathologists to ensure accuracy.
Scopio's FF-BMA Application transforms BMA analysis by combining
high-resolution Full-Field imaging with a robust AI-powered
decision support system into a fully digital workflow seamlessly
integrated with Scopio's X100 and X100HT scanners. It also enables
hematopathologists to review bone marrow smears remotely (via a
secure hospital network), potentially reducing turnaround time,
fostering collaboration, facilitating second opinions, and
bolstering diagnostic confidence.
"In today's lab, there is limited technology available to assist
in the analysis of bone marrow aspirate," said Chris Hagen, Senior Vice President and General
Manager, Core Lab Specialty Products for Beckman Coulter
Diagnostics. "With Scopio's technology, lab scientists can assess
hundreds of cells to evaluate morphological features with the
support of artificial intelligence using the world's first BMA
digital imaging and analysis solutions. Reviewers can observe
representative cell distribution across the sample at rates far
exceeding that of reviews done by manual microscopes. We are
thrilled to expand our partnership with Scopio and continue to
bring full-field, AI-powered, digital imaging innovations to
clinical labs worldwide."
"We are excited to extend our global partnership agreement with
Beckman Coulter, which exemplifies our shared mission to advance
the digital transformation of clinical laboratories around the
world," said Itai Hayut, CEO and
Co-Founder of Scopio Labs. "The addition of our first-of-its-kind
digital bone marrow application into Beckman Coulter's hematology
offering, signifies a strong endorsement of the successful adoption
of Scopio's Full-Field digital cell morphology platform in the
market to date. We look forward to continuing our partnership as
Scopio brings new products to the market to fulfill the potential
of hematology diagnostics in this new digital era."
Since 2022, Beckman Coulter and Scopio have been working
together to accelerate adoption of the next generation of digital
cell morphology. Scopio's X100 and X100HT digital cell morphology
platforms employ full-field imaging and AI decision support
eliminating the need for manual microscopy, while providing
laboratory scientists and physicians true workflow benefits with
simple to use remote viewing through a secured network.
In 2023, Beckman Coulter Diagnostics announced a new end-to-end
automated hematology solution by connecting its DxH 900 Workcell
and DxH Slidemaker Stainer II with the Scopio X100HT
high-throughput digital cell morphology platform, complete with
digitalized, AI-assisted peripheral blood smear analysis.
Availability of Scopio Labs' Full-Field Peripheral Blood Smear™
Application and Full-Field Bone Marrow Aspirate™ Application may
vary by region. To learn more, visit
www.beckmancoulter.com/scopio.
Follow and connect with Beckman Coulter
via LinkedIn, X, and Facebook.
About Beckman Coulter Diagnostics
A global leader in advanced diagnostics, Beckman
Coulter has challenged convention to elevate the diagnostic
laboratory's role in improving patient health for nearly 90 years.
Our mission is to Relentlessly Reimagine Healthcare, One
Diagnosis at a Time – and we do this by applying the power of
science, technology and the passion and creativity of our teams.
Our diagnostic solutions are used in complex clinical testing, and
are found in hospitals, reference laboratories and physician office
settings around the globe. We exist to deliver smarter, faster
diagnostic solutions that move the needle forward from what's now
to what's next. We do this by accelerating care with an extensive
clinical menu, scalable lab automation technologies, insightful
clinical informatics, and optimize lab performance services.
Beckman Coulter, part of the Danaher Corporation (NYSE:DHR) family
of global science and technology companies. Headquartered in
Brea, Calif., has more than 11,000
global team members.
About Scopio
Scopio Labs is the developer of full-field digital imaging for
hematology diagnostics. By supporting laboratory scientists and
clinicians with unprecedented scale and depth in digital cell
morphology, the company's platforms enable timely detection of
blood-related medical conditions, expediting patients' access to
life-saving treatments.
Scopio solves cell morphology's age-old trade-off between
resolution and field of view. Its high-resolution imaging and
embedded AI combine for more efficient remote workflow,
contributing to better diagnostics across the continuum of
care.
Scopio Labs' Full-Field Peripheral Blood Smear Application and
Full-Field Bone Marrow Aspirate Application are FDA-cleared and
CE-marked for use with the Scopio X100 and Scopio X100HT platforms.
To learn more, visit www.scopiolabs.com.
© 2024 Beckman Coulter. All rights reserved. Beckman Coulter,
the stylized logo, and the Beckman Coulter product and service
marks mentioned herein are trademarks or registered trademarks of
Beckman Coulter, Inc. in the United
States and other countries. 2024-13489
i Lewis JE, Pozdnyakova O. Digital assessment of
peripheral blood and bone marrow aspirate smears. Int J Lab
Hematol. 2023 Jun;45 Suppl 2:50-58. doi: 10.1111/ijlh.14082. Epub
2023 May 21. PMID: 37211430.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/beckman-coulter-and-scopio-labs-add-worlds-first-digital-bone-marrow-imaging-and-analysis-to-long-term-partnership-302249748.html
SOURCE Beckman Coulter Diagnostics